| Psoriasis: Treatment and Pathogenesis | Lifetime | 132 | US 51 | 98.74 |
| Spondyloarthritis Studies and Treatments | Lifetime | 119 | US 31 | 98.70 |
| Dermatology and Skin Diseases | Lifetime | 312 | US 94 | 98.39 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 286 | US 91 | 98.13 |
| Autoimmune Bullous Skin Diseases | Lifetime | 357 | US 122 | 97.41 |
| Systemic Lupus Erythematosus Research | Lifetime | 866 | US 283 | 97.57 |
| Rheumatoid Arthritis Research and Therapies | Lifetime | 639 | US 167 | 97.51 |
| Autoimmune and Inflammatory Disorders | Lifetime | 557 | US 175 | 92.62 |
| Hidradenitis Suppurativa and Treatments | Lifetime | 313 | US 83 | 85.39 |
| Dermatological and COVID-19 studies | Lifetime | 560 | US 155 | 80.75 |
| Psoriasis: Treatment and Pathogenesis | 2021-2025 | 4 | US 3 | 99.81 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 7 | US 2 | 99.70 |
| Spondyloarthritis Studies and Treatments | 2021-2025 | 7 | US 2 | 99.70 |
| Dermatology and Skin Diseases | 2021-2025 | 30 | US 12 | 99.52 |
| Rheumatoid Arthritis Research and Therapies | 2021-2025 | 45 | US 14 | 98.89 |
| Autoimmune Bullous Skin Diseases | 2021-2025 | 33 | US 12 | 98.53 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 86 | US 30 | 98.36 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 33 | US 12 | 95.46 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 318 | US 106 | 94.67 |
| Asthma and respiratory diseases | 2021-2025 | 402 | US 109 | 96.41 |
| T-cell and B-cell Immunology | 2021-2025 | 299 | US 131 | 92.39 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 810 | US 265 | 93.84 |
| Urticaria and Related Conditions | 2021-2025 | 152 | US 27 | 93.63 |
| Pharmaceutical studies and practices | 2021-2025 | 166 | US 64 | 90.34 |
| Fibromyalgia and Chronic Fatigue Syndrome Research | 2021-2025 | 273 | US 64 | 90.69 |
| Pregnancy and Medication Impact | 2021-2025 | 262 | US 86 | 88.59 |
| Autoimmune and Inflammatory Disorders | 2021-2025 | 161 | US 53 | 86.31 |
| Food Allergy and Anaphylaxis Research | 2021-2025 | 884 | US 205 | 80.55 |
| Dermatological and COVID-19 studies | 2021-2025 | 379 | US 61 | 65.73 |
| Drug-Induced Adverse Reactions | 2021-2025 | 990 | US 207 | 64.78 |
| Hidradenitis Suppurativa and Treatments | 2021-2025 | 479 | US 152 | 63.74 |
| Retinoids in leukemia and cellular processes | 2021-2025 | 728 | US 217 | 55.99 |
| Therapeutic Uses of Natural Elements | 2021-2025 | 592 | US 61 | 41.33 |
| Medicine and Dermatology Studies History | 2021-2025 | 447 | US 227 | 35.60 |
